Phenotypical and functional heterogeneity of the large granular lymphocytes increased after various treatments in a patient with combined immunodeficiency
- PMID: 2649508
- DOI: 10.1007/BF00917126
Phenotypical and functional heterogeneity of the large granular lymphocytes increased after various treatments in a patient with combined immunodeficiency
Abstract
A boy with combined immunodeficiency having low natural killer (NK)-cell activity received thymopoietin pentapeptide (TP-5) treatment, transplanted with T cell-depleted HLA-haploidentical bone marrow (BMT) cells from his father and with thymus tissue from an infant at different times during the first year of life. He showed a marked increase in large granular lymphocytes (LGL) both during the treatment with TP-5 and after BMT. The LGL generated following TP-5 injection had a T3+Leu11- surface phenotype and low NK activity. In contrast, the LGL appearing after BMT showed T3-, Leu7+, and/or Leu11+ surface phenotypes, had high NK- and K-cell activities, and were lymphokine-activated killer (LAK)-cell precursors. These killer activities were assigned to the Leu7-Leu11+ subset and proved to be of recipient origin. LGL proliferation following BMT was accompanied by neutropenia, which was improved in association with a reduction in the number of LGL and the appearance of T cells of BMT donor origin following thymus transplantation. This suggested the inhibition of granulopoiesis by the LGL and an in vitro study revealed that the Leu7+Leu11- subset of LGL suppressed the growth of granulocyte/macrophage colony-forming units. These results indicated that phenotypically different LGL could be generated by different treatments and that the LGL showing NK activity were distinct from those regulating granulopoiesis. It was also suggested that the generation of LGL was controlled by T cells.
Similar articles
-
Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency.Clin Exp Immunol. 1981 Aug;45(2):344-51. Clin Exp Immunol. 1981. PMID: 7032772 Free PMC article.
-
Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome.Prog Clin Biol Res. 1989;308:995-9. Prog Clin Biol Res. 1989. PMID: 2528748 No abstract available.
-
Bone marrow transplantation and thymopoietin pentapeptide treatment in two infants with immunodeficiency with predominant T-cell defects.Clin Immunol Immunopathol. 1984 Oct;33(1):123-30. doi: 10.1016/0090-1229(84)90298-8. Clin Immunol Immunopathol. 1984. PMID: 6383671
-
Thymopentin in dermatology.Curr Probl Dermatol. 1989;18:283-9. doi: 10.1159/000416866. Curr Probl Dermatol. 1989. PMID: 2663371 Review. No abstract available.
-
Immunostimulation by TP-5 in immunocompromised patients and animals--current status of investigation.Comp Immunol Microbiol Infect Dis. 1986;9(2-3):225-32. doi: 10.1016/0147-9571(86)90015-9. Comp Immunol Microbiol Infect Dis. 1986. PMID: 3539496 Review.
Cited by
-
Three novel mutations in the interleukin-2 receptor gamma chain gene in four Japanese patients with X-linked severe combined immunodeficiency.Hum Genet. 1995 Dec;96(6):681-3. doi: 10.1007/BF00210299. Hum Genet. 1995. PMID: 8522327
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials